Recent research published in Cancer Research highlights a novel mechanism of MYO1G pyroptosis regulation that allows cancer cells to evade programmed death. While the N-terminal fragments of gasdermin E (GSDME-NT) typically form lethal pores on the plasma membrane, some cells exhibit unexpected resilience. Researchers have now identified Myosin 1G (MYO1G) as a critical protein that facilitates the removal of these pores, thereby restraining the efficacy of chemotherapy in clinical settings.

Mechanisms of MYO1G Pyroptosis Regulation

The study describes how MYO1G tethers GSDME-NT pores to caveolin-1 (CAV1) to ensure cell survival. This interaction promotes the caveolin-1-mediated endocytosis of the pyroptotic pores before the cell membrane can rupture. Consequently, the cell effectively \"repairs\" itself during the early stages of death signaling. This process begins with the release of intracellular α-ketoglutarate (α-KG), which stabilizes HIF1α and transcriptionally upregulates MYO1G. Therefore, the stress of pyroptosis initiation inadvertently induces a protective feedback loop in resistant cancer cells.

Clinical Implications for Cancer Therapy

Clinically, high levels of MYO1G correlate with poor short-term responses to cisplatin-based chemotherapy. This finding is particularly relevant in nasopharyngeal carcinoma (NPC), where MYO1G also serves as a biological indicator of unfavorable long-term survival. Moreover, pharmacological inhibition of MYO1G or cholesterol synthesis can sensitize tumors to standard treatments. By promoting sustained pyroptosis, these interventions boost antitumor immunity and work synergistically with chemotherapy to eradicate resistant tumors. Furthermore, understanding this protective mechanism provides a roadmap for developing more effective combination therapies in oncology.

FAQs on Gasdermin E and MYO1G

How does MYO1G prevent cell death in cancer?

MYO1G enables cells to resist death by facilitating the internalisation of gasdermin E pores through caveolin-1-mediated endocytosis, which prevents the final membrane rupture necessary for pyroptosis.

Can cholesterol inhibitors improve chemotherapy outcomes?

Yes, inhibiting cholesterol synthesis can promote pyroptosis by interfering with the caveolin-1-mediated removal of gasdermin pores, thus enhancing the overall efficacy of chemotherapeutic agents in resistant cancers.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Refer to the latest local and national guidelines for clinical practice.

References

1. Ding C et al. MYO1G Facilitates Caveolin-1-Mediated Endocytosis of the N-Terminal Fragments of Gasdermin E to Restrain Pyroptosis and Chemotherapy Efficacy. Cancer Res. 2026 May 14. doi: 10.1158/0008-5472.CAN-25-0786. PMID: 42133406.


2. Wang Y et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547(7661):99-103.


3. Zhang Z et al. Gasdermin E suppresses tumour growth via activation of anti-tumour immunity. Nature. 2020;579(7799):415-420.